Abiraterone Acetate Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 250 mg, 500 mg

Reference Brands: Zytiga®(EU & US)

Category: Oncology Cancer Care

Abiraterone Acetate Tablets are oral oncology drugs used to treat metastatic prostate cancer. Available in 250 mg and 500 mg strengths, they are approved in both the U.S. and EU, commonly marketed as Zytiga® or in generic form. Used with prednisone, Abiraterone helps block androgen production and slow cancer growth. Abiraterone Acetate is available in Tablet and strengths such as 250 mg, 500 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Abiraterone Acetate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Abiraterone Acetate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Abiraterone Acetate Tablets, available in 250 mg and 500 mg strengths, are a key oral oncology product used in treating metastatic prostate cancer. Approved across the U.S. and EU, Abiraterone inhibits androgen biosynthesis by targeting the CYP17 enzyme, effectively suppressing tumor growth in hormone-sensitive prostate cancers. Marketed under the brand name Zytiga® and widely available as generics, this therapy is often used alongside prednisone. Abiraterone Acetate is a vital product for pharma B2B oncology portfolios, offering significant therapeutic benefit and global demand in both hospital and retail oncology markets.